L,-A retrospective analysis is presented of factors affecting the length of survival of 285 consecutive adults with newly diagnosed biopsy-proven supratentorial anaplastic glioma (188 cases of glioblastoma multiforme, 76 of anaplastic astrocytoma, 11 of anaplastic mixed glioma, and 10 of anaplastic oligodendroglioma) treated at a regional cancer center from July, 1982, through December, 1987. The approach to initial therapy included maximum feasible resection and radiotherapy. The median survival time for all patients was 35 weeks. Multivariate analysis demonstrated that age, duration of symptoms, preirradiation performance status, tumor histology, accessibility to resection, extent of resection, radiotherapy, and prior low-grade glioma were significant independent variables influencing survival. The prognostic importance of age, duration of symptoms, performance status, and tumor histology are already recognized, but three "new" findings are reported. First, patients with anaplastic oligodendroglioma had the longest median survival time (278 weeks). Second, corrected for accessibility and all other variables, patients with gross total resection lived longer than those with partial resection, and patients with any degree of resection lived longer than those who underwent only a biopsy procedure. Third, patients with anaplastic glioma in whom there was a prior history of low-grade glioma lived significantly longer after the diagnosis of anaplastic glioma than did patients in whom the anaplastic glioma apparently arose de novo.
S
URVIVAL predictions for patients with anaplastic glioma are based on a variety of factors and derived from the results of large multicentered, prospective, randomized clinical trials and smaller single-institution retrospective studies. 2"4J~'9 14,17,19 21,24,28 30 The literature suggests a median period of survival after diagnosis of 40 to 60 weeks, and there is general agreement that age at diagnosis, duration of symptoms, performance status after surgery, and tumor histology are important independent predictors of outcome. 2"f2"1928"29 We report a retrospective analysis of prognostic factors and survival times at a center where the experience with anaplastic glioma is populationbased.
Clinical Material and Methods

Patient Population
The London Regional Cancer Centre (LRCC) is a regional cancer treatment facility and the sole radiotherapy (RT) unit in central southwestern Ontario (with an estimated population of 1.1 million). It is a division of the Ontario Cancer Treatment and Research Foundation (the provincial cancer network) and is affiliated with the University of Western Ontario and its teaching hospitals. Similarly, the University's Department of Clinical Neurological Sciences is the region's principal neurodiagnostic and neurosurgical unit. As a direct result of this organizational framework and our interest in brain tumor, virtually all patients with anaplastic glioma in the region are evaluated, treated, and followed by one of us (D.R.M. or J.G.C.).
The records were reviewed of all adults (age _> 18 years) with newly diagnosed, biopsy-proven, supratentorial anaplastic glioma seen at the LRCC between July, 1982 and December, 1987. The review period included time during which our center was one of five participating in a prospective randomized clinical trial assessing two comparably and modestly toxic intravenous drugs. (The other four centers were: Duke University Medical Center (coordinating center), the University of North Carolina, Northwestern University-Evanston Hospital, and the University of Alabama.) For the trial protocol, randomization occurred 8 weeks after the completion of RT (approximately 17 weeks after surgery). Trial and nontrial patients were included in the present review. A surgical tissue diagnosis had been performed in all patients. Most patients had undergone an open biopsy followed by maximum feasible tumor resection. Stereotactic biopsies were not performed. All patients received adrenocorticosteroids (steroids) preoperatively, postoperatively, and during the early phases of RT. Subsequently, steroids were used only as necessary to control or minimize cerebral symptoms. Steroids were not used to prolong terminal situations. The RT dosage was uniform for most patients (4400 cGy in 22 fractions to the whole brain, plus 1400 cGy in eight fractions as a focal boost, over 6 weeks) and usually began within 3 weeks of surgery. The histological criteria for diagnosis of anaplastic glioma were those of Burger, et al. 2 Patients with glioblastoma multiforme, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, and anaplastic mixed glioma were included in this analysis. All patients had comprehensive health care insurance through a government-subsidized program. Financial considerations were not a barrier to diagnosis or treatment. Not included in this analysis were 28 severely disabled elderly patients with clinical and radiographic evidence of anaplastic glioma in whom a tissue diagnosis was not obtained because their families or physiciaosjudged treatment to be ill-advised.
Study Method
The date of diagnosis and date of death (or last known status) were recorded for all patients. The following factors were evaluated for prognostic significance: age at diagnosis; gender; duration of symptoms; seizures; tumor lateralization; tumor location; accessibility to resection; extent of resection; tumor histology; Karnofsky performance status ~5 (KPS); RT; and presence of prior suspected or proven low-grade glioma. The interval between the onset of symptoms of anaplastic glioma and tissue diagnosis was considered the duration of symptoms. Any recent neurological problem that could be explained by the anaplastic glioma or any recent change in a previously stable or chronic neurological disorder, such as a change in seizure character or frequency, was considered the first symptom. The prognostic importance of seizures was examined in three ways: was there a history of epilepsy prior to diagnosis; were seizures the initial symptom of anaplastic glioma; and did seizures occur at any time before or after the diagnosis of anaplastic glioma? All tumors were recorded as right-sided, left-sided, or bilateral. Tumor location was considered as the area or lobe in which the tumor was predominantly located. Categories included frontal, temporal, parietal, and occipital lobes, corpus callosum, basal ganglia, and thalamus. Tumors involving the basal ganglia and thalamus were considered inaccessible to surgical resection, and tumors in all other locations were considered surgically accessible. The extent of resection was recorded from the operative notes. Categories included biopsy, partial resection, partial resection with lobectomy, and gross total resection. The KPS was examined 3 and 9 weeks after diagnosis (that is, pre-RT and post-RT). Based on the histological diagnosis, all patients were assigned to one of two categories: giioblastoma multiforme (including gliosarcoma) or anaplastic glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, and anaplastic mixed glioma). Patients were separated into two groups: those who received adequate postoperative RT and those who did not. Patients who received at least 5000 cGy to the tumor were considered to have received adequate RT. Patients were also divided into those in whom there was a prior suspected or proven low-grade glioma and those in whom the anaplastic glioma appeared to arise de novo. Patients were suspected of having a low-grade glioma if they had chronic focal seizures (for _~ 18 months) from an area of brain where the anaplastic glioma was subsequently detected. They were also suspected of harboring a low-grade glioma if they had suffered focal or generalized seizures or progressive focal neurological deficits (such as aphasia, paresis, or sensory loss) for a minimum of 18 months and a hypodense, nonenhancing lesion was found on computerized tomography (CT) in the area of brain where the anaplastic glioma subsequently developed. Patients with prior proven low-grade glioma met the aforementioned clinical and radiographic criteria and in addition had biopsy-proven low-grade glioma (astrocytoma or oligodendroglioma) at least 18 months prior to the diagnosis of anaplastic glioma. Patients with prior low-grade glioma had a distinct biphasic illness with initial symptoms that were stable and controlled followed by acute or subacute deterioration. None of the suspected or proven low-grade glioma patients had received RT.
The end-point of this study was the period of survival. Survival was measured from the time of definitive surgical diagnosis to date of death. Median survival times were compared using the generalized Wilcoxon test (Breslow). Survival curves were generated using the life-table method, s Univariate analysis identified those factors associated with a significant influence on survival times (p _< 0.05). For a study of the prognostic importance of multiple factors acting simultaneously, the proportional hazards regression model of Cox 7 was used in which survival times were modeled as a function of the important variables identified in the univariate analysis. Multivariate analysis permitted the identification of significant independent prognostic factors (that is, variables having a significant impact on survival independent of all other factors recognized and included in the analysis). No attempt was made to rank or assign relative importance to those factors identified as independently significant in the multivariate analysis. Age and duration of symptoms were analyzed as continuous variables but, for ease of comparison, spe-Prognosis in supratentorial anaplastic gliomas cific age categories and durations were selected for presentation (Table 1) . Partial resection was combined with partial resection with lobectomy in the multivariate analysis. The KPS at 9 weeks after surgery was omitted from the multivariate analysis because 61 patients (21%) could not be evaluated in this respect: 58 died within 9 weeks of surgery and three were lost to follow-up review. Chemotherapy was omitted from this analysis because it was not a part of the initial treatment (there was a 17-week delay from diagnosis in the protocol) and only a minority of patients (31%) received cytotoxic drugs.
Results
There were 285 adults (157 men and 128 women, mean age 57 years) with newly diagnosed biopsy-proven supratentorial anaplastic glioma treated at the LRCC from July, 1982, through December, 1987. The median interval from first symptom to diagnosis was 8 weeks. The distribution of tumor types was as follows: 188 cases of glioblastoma multiforme, 76 of anaplastic astrocytoma, 11 of anaplastic mixed glioma, and 10 of anaplastic oligodendroglioma; thus, glioblastoma multiforme accounted for 66% of cases and anaplastic glioma for 34%. The median survival time for all patients was 35 weeks.
The results of the univariate and multivariate analyses are summarized in Table 1 . Age at diagnosis, duration of symptoms, seizure as the initial symptom of anaplastic glioma, accessibility to resection, extent of resection, tumor histology, KPS at 3 and 9 weeks after surgery, delivery of RT, and prior low-grade glioma were all statistically significant in the univariate analysis. Gender and tumor lateralization were not significant factors. Tumor location was significant only when anaplastic gliomas of the thalamus and basal ganglia (that is, tumors inaccessible to resection) were compared to those in other sites (that is, tumors accessible to resection). There was no difference in survival among patients with frontal, parietal, temporal, or occipital tumors. There was a tendency for patients with bihemispheric tumors or tumors of the corpus callosum to fare less well. Age at diagnosis, duration of symptoms, seizure as the initial manifestation of anaplastic glioma, accessibility to resection, extent of resection, tumor histology, KPS 3 weeks after surgery, delivery of RT, and prior low-grade glioma were included in the multivariate analysis. All proved to be significant independent variables with the exception of seizure as the initial symptom of anaplastic glioma.
Age at diagnosis was a significant independent variable. Younger patients lived longer than older ones. Median survival time from diagnosis was 107 weeks for patients aged 18 to 44 years, 42 weeks for those aged 45 to 65 years, and 23 weeks for those aged over 65 years (p < 0.0001). Symptom duration was a significant independent prognostic factor: patients with longer durations of symptoms lived longer. Median survival time was 35 weeks for patients with symptoms lasting 16 weeks or less and 88 weeks for those with symptoms of longer than 16 weeks' duration (p = 0.0002). Tumor location was a significant independent variable only with respect to accessibility to resection; patients with surgically accessible lesions lived significantly longer (p = 0.0001). Extent of resection, corrected for accessibility and all other variables, was a significant independent prognostic factor (Fig. 1) . Patients with gross total resection lived significantly longer than those with partial resection, and patients with any degree of resection lived significantly longer than those undergoing only a biopsy procedure. Median survival time for patients with biopsy only was 19 weeks; for those with partial resection without or with lobectomy 41 and 47 weeks, respectively (p = 0.2106); and for those with gross total resection 76 weeks.
Tumor histology was a significant independent variable (Fig. 2) . Median survival times were as follows: glioblastoma multiforme, 32 weeks; anaplastic astrocytoma, 63 weeks; anaplastic mixed glioma, 57 weeks; FIG. 1. Survival curves for patients with gross total resection, subtotal resection with lobectomy, subtotal resection, and tumor biopsy. and anaplastic oligodendroglioma, 278 weeks. Patients with anaplastic astrocytoma and anaplastic mixed glioma had comparable median survival times (p = 0.4046). Patients with anaplastic oligodendroglioma lived significantly longer than patients with either anaplastic astrocytoma or anaplastic mixed glioma, who in turn lived significantly longer than patients with glioblastoma multiforme. However, following the multivariate analysis, tumor histology was significant only insofar as patients with anaplastic glioma (that is, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic mixed glioma) lived significantly longer than patients with glioblastoma multiforme. Median survival time for patients with anaplastic oligodendroglioma, although substantially longer, did not reach statistical significance when all variables were considered simultaneously.
The KPS 3 weeks after surgery was a significant independent prognostic factor. Patients with better function lived longer. Median survival times in three performance categories were as follows: KPS score 20 to 40, 15 weeks; KPS score 50 to 70, 36 weeks; and KPS score 80 to 100, 76 weeks (p < 0.0001). Delivery of RT was a significant independent variable: 235 patients received adequate treatment; 41 patients deteriorated despite surgery and were not irradiated; and nine patients began RT but received less than 5000 cGy to the tumor. Radiation therapy was stopped due to clinical deterioration in seven patients, and two patients refused to continue treatment. Median survival times for patients with or without RT were 48 and 17 weeks, respectively (p = 0.0001).
A prior low-grade glioma was a significant independent prognostic factor (Fig. 3) . A preexisting low-grade glioma was suspected in 19 patients and proven by biopsy in nine (seven astrocytoma, two oligodendroglioma). The diagnosis of low-grade glioma was suspected on the basis of clinical and CT evidence in 13 patients and appropriately localizing focal seizures with-FIG. 2. Survival curves for patients with anaplastic oligodendroglioma, anaplastic astrocytoma, anaplastic mixed glioma, and glioblastoma multiforme. 
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out radiographic confirmation were recorded in six. Seizures were the initial and principal neurological symptom in all patients with low-grade glioma. One patient had a slowly progressive monoparesis in addition to seizures. Median duration of symptoms from first seizure to diagnosis of anaplastic glioma was 3 years (range 1.5 to 1 1 years). The median duration of clinical deterioration prior to diagnosis of an anaplastic glioma was 11 weeks. Patients with anaplastic glioma and a history of low-grade glioma were younger and had a more favorable tumor histology and superior KPS after surgery than other patients ( Table 2 ). The extent of resection was similar in both groups. Median survival time for patients with prior low-grade glioma was 162 weeks compared to 38 weeks for the others (p = 0.0001). Prior low-grade glioma remained a significant independent prognostic factor when corrected for age at diagnosis, tumor histology, KPS, and all other variables.
Discussion
Randomized clinical trials and single-institution retrospective studies are the principal sources of data on prognostic factors and periods of survival for patients with anaplastic glioma. Predictions based on the results of these studies have potential limitations and inaccuracies due to selection bias and other methodological problems. For example, randomized clinical trials invariably study the treatment of a nonrepresentafive subset of patients with anaplastic glioma by excluding those who do poorly at the outset and those with a poor KPS) ~ Conclusions based on the analysis of selected patients with anaplastic glioma may not apply to all patients with the disease. Single-institution retrospective studies, particularly those from tertiary university hospitals and cancer centers, are also vulnerable to selection bias and, in addition, may have limitations imposed by missing data, incomplete follow-up data, and so on. The present single-institution retrospective study is different in two important respects and overcomes some of the albrementioned difficulties. First, the LRCC is a regional cancer center, not a tertiary referral center and, as such, has a defined patient constituency. Two of us (D.R.M. and J.G.C.) are fortunate to examine, participate in the management of, and follow virtually all patients in our region with diagnosed anaplastic glioma. Thus, our conclusions with respect to prognostic factors and survival times are based on an evaluation of "all" patients with the disease. Second, this retrospective analysis is unusual as it is a review of "all" patients assessed for a prospective randomized clinical trial. Because all patients were potentially studyeligible, thorough records were kept and there was a uniform approach to initial therapy. Age at diagnosis, duration of symptoms, and KPS after surgery have been established as significant prognostic factors in virtually every major clinical trial and retrospective analysis. 2"5"6"~2"13a928"29 Their prognostic importance has been reaffirmed in this analysis. The presence of seizures, or seizures as the initial symptom of anaplastic glioma, has been identified as a favorable factor in several studies. ~2, 26, 28, 29 We were unable to demonstrate that seizures were a significant independent prognostic factor. Duration of symptoms and prior low-grade glioma were the variables that eliminated seizures as a significant independent factor when the Cox regression was performed in a stepwise fashion. The delivery of RT has been shown to significantly prolong survival times in a prospective randomized trial conducted by the Brain Tumor Study Group (BTSG) 28 and in this and other retrospective studies? t,3o
The prognostic importance of tumor histology has been demonstrated in numerous clinical trials and retrospective studies, 269~2~9~29 based on either the four-tier system of Kernohan and Sayre J6 or the now more widely employed three-tier system of Ringertz, 23 modified by Burger and Vogel. 1.2 Tumor histology was not found to be an important prognostic factor in a Southwest Oncology Group (SWOG) study, ~~ but small sample size and unusual histological categories (astrocytoma grade III, astrocytoma grade III-IV, astrocytoma grade IV) may explain this. At the LRCC, patients with anaplastic glioma lived significantly longer than those with glioblastoma multiforme. We also observed that patients with anaplastic oligodendroglioma lived much longer (median survival time 278 weeks) than patients in all other tumor groups; however, we were unable to demonstrate that anaplastic oligodendroglioma was a significant variable independent of all other factors. The combination of small sample size (10 patients), younger age at diagnosis, longer duration of symptoms, and a history of low-grade glioma in five patients with anaplastic oligodendroglioma may account for the loss of statistical significance in the multivariate analysis. We suggest that the prognostic importance of anaplastic oligodendroglioma be reevaluated in a larger series of patients and suspect that this tumor has a more favorable natural history and a better response to treatment. The longer median survival times of the anaplastic oligodendroglioma group in this study were favora-bly influenced by successful chemotherapy at recurrence in five patients. 3 The influence of extent of tumor resection on survival times has been debated. Jelsma and Bucy 14 advocated extensive resection based on their analysis of 162 patients with glioblastoma multiforme. Similar recommendations have come from retrospective studies.lL 13,27 Hirakawa, et aL, 13 found extent of tumor resection to be a significant prognostic factor independent of age, duration of symptoms, tumor location, number of operations, and performance status at discharge, but they omitted tumor histology from the analysis. Randomized clinical trials have produced conflicting results. In an early study, the BTSG (69-01) concluded that bulk resection was superior to biopsy. 28 In a subsequent study (BTSG 75-01), it was found that patients with gross total resection with lobectomy lived longer than those with gross total resection, and both groups lived longer than biopsied patients. 12 However, the type and extent of resection were not statistically significant when all variables were considered simultaneously. The SWOG concluded that extent of resection was not an important prognostic factor in a study that controlled for age at diagnosis, tumor histology, and performance status. 1~ Nelson, et aL, 19 in a review of serial Radiation Therapy Oncology Group (RTOG) studies, found that extent of resection was a significant prognostic factor independent of age at diagnosis, tumor histology, and performance status at randomization, but they omitted tumor accessibility to resection from the analysis.
The prognostic importance of extent of resection has also been examined using CT scan data. Two recent studies have demonstrated a correlation between postoperative tumor size on CT and period of survivalJ s '23 Patients with smaller tumors after surgery lived significantly longer. There was no correlation between preoperative tumor size on CT and length of life. 22'32 The present series of unselected patients demonstrates for the first time that extent of resection is a significant prognostic factor independent of tumor location and all other variables. In this series, patients with gross total resection lived longer than those with partial resection, and patients with any degree of resection lived longer than those only receiving biopsy. Lobectomy did not improve survival time in the subtotal resection group. Our preliminary analysis of pre-and postoperative CT scans suggests that extent of resection estimated from CT scans is also a significant independent prognostic factor. It is possible that extent of resection is influenced by a variable not included in this or other studies; namely, KPS prior to surgery. We suggest that performance status prior to surgery be systematically recorded and analyzed in future studies of prognostic factors.
Twenty-eight patients in this study had a history of suspected or proven low-grade glioma. These patients lived significantly longer than the others. The prognostic importance of prior low-grade glioma has been alluded to previously, 2~ and this observation requires confirmation and may merit further study. If true, anaplastic gliomas arising de novo are more aggressive than those evolving from indolent tumors. This difference in clinical behavior suggests important biological, perhaps molecular, differences. Conceivably, different oncogenes or sets of oncogenes are active in de novo as compared to evolving anaplastic gliomas.
